Results 1 to 10 of about 29,046 (192)

Fondaparinux

Italian Journal of Medicine, 2013
AIM OF THE STUDY To review the best evidence-based knowledge about the clinical pharmacology and use of fondaparinux. DESIGN OF THE STUDY Narrative review. RESULTS Fondaparinux is a synthetic pentasaccharide anticoagulant that binds selectively with high
G. Airoldi, M. Campanini
doaj   +4 more sources

Associação entre o Uso de Fondaparinux com Acesso Radial e Desfechos Clínicos em Pacientes com Síndrome Coronariana Aguda sem Supradesnivelamento do Segmento ST [PDF]

Arquivos Brasileiros de Cardiologia
Resumo Fundamento: Tanto o fondaparinux quanto o acesso radial têm sido associados a menores taxas de eventos adversos cardiovasculares maiores (MACE) em pacientes com síndrome coronariana aguda (SCA).
Luiz Eduardo Fonteles Ritt, Eduardo Sahade Darze, Pedro Gabriel Melo de Barros e Silva, Gilson Soares Feitosa-Filho, João Victor Santos Pereira Ramos, Márcia A. Viana, Priscila Neri Lacerda, Emanoela Lima Freitas, Queila Oliveira Borges, Adriano Oliveira Martins, Renato Delascio Lopes   +10 more
doaj   +2 more sources

Fondaparinux Sodium: Recent Advances in the Management of Thrombosis

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for the prevention and treatment of venous thromboembolic events, that is, deep vein thrombosis, pulmonary embolism, and superficial vein thrombosis, in acutely ill ...
Rupert M Bauersachs
exaly   +2 more sources

Evaluating the impact of continuous venovenous hemodiafiltration on the efficacy of prophylactic fondaparinux doses: a prospective single-center observational study [PDF]

Scientific Reports
Critically ill patients often need continuous renal replacement therapy (CRRT). This process can remove particles as large as 10 kDa, including medications such as fondaparinux.
Aleksander Aszkiełowicz, Karol P. Steckiewicz, Radosław Owczuk   +2 more
doaj   +2 more sources

Efficacy and safety of fondaparinux in elective total hip arthroplasty and hip fracture surgery: a systematic review and meta-analysis [PDF]

Journal of Orthopaedic Surgery and Research
Background As life expectancy increases, the incidence of hip fractures and the demand for total hip arthroplasties (THA) are expected to rise. This demographic shift poses significant challenges, particularly in managing post-operative complications ...
Gonzalo Mariscal, Francisco José Tarazona-Santabalbina, Oliver Marin-Peña, Erika Rotavista, Sara Arroyo Martín, María Estrella Fernández de Sevilla, Jesús Gómez-Vallejo   +6 more
doaj   +2 more sources

Maculopathy after long-term use of fondaparinux, a heparin mimetic and heparanase inhibitor [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report maculopathy associated with the long-term use of fondaparinux, a heparin mimetic and inhibitor of the extracellular matrix enzyme, heparanase.
Benjamin R. Lin, Erick Rivera-Grana, Wenting Zhou, Mark Barakat, Philip J. Rosenfeld, Janet L. Davis   +5 more
doaj   +2 more sources

Use of fondaparinux in patients with heparin-induced thrombocytopenia on veno-venous extracorporeal membrane oxygenation: A three-patient case series report

Frontiers in Medicine, 2023
Heparin-induced thrombocytopenia is a life-threatening immune-mediated complication of unfractionated heparin therapy. Fondaparinux is a therapeutic alternative, but it has limited evidence for its use in patients on extracorporeal membrane oxygenation ...
Jitka Rychlíčková, Jitka Rychlíčková, Jitka Rychlíčková, Vladimír Šrámek, Vladimír Šrámek, Pavel Suk, Pavel Suk   +6 more
doaj   +1 more source

Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. Heparin-induced thrombocytopenia associated to hemodialysis is rare. In case when citrate dialysis and/or non-heparin anticoagulants are not available, only possible medication to use for anticoagulation during hemodialysis is ...
Kušić Jovana, Kulić Andrijana, Đurković Veselinka, Marković Rodoljub, Milačić Velja, Surić-Lambić Ljiljana, Peković Gordana   +6 more
doaj   +1 more source

Study on the safety and effectiveness of low-dose vs. regular-dose fondaparinux in preventing venous thromboembolism prophylaxis following total knee arthroplasty

Frontiers in Cardiovascular Medicine, 2023
BackgroundThis study aims to evaluate the effectiveness and safety of low-dose (1.5 mg) fondaparinux for venous thromboembolism (VTE) prophylaxis in patients post-total knee arthroplasty (TKA).MethodsWe retrospectively identified 314 patients who carried
Ping-bo Chen, Jing Wang, Lei Wang, Shou-liang Xiong, Chao Wang, Xin Yang, Cong-ming Li, Qiang Wang, Yin-chang Zhang   +8 more
doaj   +1 more source

Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban

Platelets, 2020
HIT, a prothrombotic disorder caused by heparin-dependent antibodies, is often treated with fondaparinux, usually with good outcomes. A 70-year-old female developed severe HIT (platelet count, 25 × 109/L) post-glioblastoma resection during heparin ...
Farheen Manji, Theodore E. Warkentin, Jo-Ann I. Sheppard, Adrienne Lee   +3 more
doaj   +1 more source